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What is already known on this topic?
 ► Mucopolysaccharidosis type I (MPS I) is an 
inherited lysosomal storage disease where 
affected individuals experience significant 
disease burden, disability and premature death.
 ► Early treatment with enzyme replacement 
therapy and/or haematopoietic stem cell 
transplantation can reduce/halt disease 
progression and improve outcomes. However, 
diagnosis, and consequently the start of 
therapy, is often delayed, particularly for 
patients with attenuated phenotypes.
What this study adds?
 ► Our analyses show that while time to diagnosis 
for attenuated MPS I is still delayed, time to 
treatment has improved significantly over the 
15 years since enzyme replacement therapy was 
introduced.
ABSTRACT
Objective Early diagnosis and treatment initiation 
are important factors for successful treatment of 
mucopolysaccharidosis type I (MPS I). The purpose of 
this observational study was to assess whether age at 
diagnosis and time to first treatment for individuals with 
MPS I have improved over the last 15 years.
Study design Data from the MPS I Registry 
(NCT00144794) for individuals with attenuated or severe 
disease who initiated therapy with laronidase enzyme 
replacement therapy (ERT) and/or hematopoietic stem 
cell transplantation (HSCT) between 1 January 2003 and 
31 December 2017 were included.
Results Data were available for 740 individuals with 
attenuated (n=291) or severe (n=424) MPS I (unknown 
n=25). Median age at diagnosis for attenuated disease 
did not change over time and ranged between 4.5 and 6 
years of age while the median duration from diagnosis to 
first ERT decreased from 5.6 years before/during 2004 to 
2.4 months in 2014–2017. For severe MPS I treated with 
HSCT, median age at diagnosis was less than 1 year and 
median time to first treatment was less than 3 months 
throughout the 15- year observation period.
Conclusions Times to diagnosis and HSCT initiation 
for individuals with severe MPS I were consistent over 
time. For individuals with attenuated MPS I, the time to 
ERT initiation after diagnosis has improved substantially 
in the last 15 years, but median age at diagnosis has 
not improved. Efforts to improve early diagnosis in 
attenuated MPS I are needed to ensure that patients 
receive appropriate treatment at the optimal time.
InTROduCTIOn
Mucopolysaccharidosis type I (MPS I) results from 
deficient α-L- iduronidase, a lysosomal enzyme 
responsible for glycosaminoglycans (GAGs) 
dermatan and heparan sulfate metabolism.1 MPS I 
is a pan- ethnic, autosomal- recessive disease, with an 
incidence that varies across regions and is estimated 
as 1/100 000 live births.2 3 Disease phenotypes 
range from severe (Hurler syndrome) to attenuated 
(Hurler- Scheie and Scheie syndromes) depending 
on presence or absence of central nervous system 
(CNS)/neurocognitive involvement and rate of 
disease progression.1 4 5 If untreated, MPS I results 
in significant disease burden and disability, with 
premature death possible from respiratory and 
cardiac disease.2
Treatment options include haematopoietic stem 
cell transplantation (HSCT) for severe disease, and 
enzyme replacement therapy (ERT) with laronidase 
(recombinant human α-L- iduronidase; Aldura-
zyme) for treatment of non- CNS manifestations of 
MPS I6–9 and in the peritransplant period for severe 
disease.10 Treatment outcomes are influenced both 
by disease severity and age at treatment initia-
tion.11 12 Early treatment considerably improves 
patient outcomes during long- term therapy and is 
crucial to reduce or halt disease progression before 
irreversible damage occurs.12–16 However, diagnosis 
of MPS I is often delayed, particularly for patients 
with attenuated phenotypes, resulting in delayed 
introduction of treatment.17–23
Data from the MPS I Registry were analysed 
to understand trends in diagnosis and treatment 
in individuals with severe or attenuated MPS I 
since introduction of ERT and to identify poten-
tial factors influencing delays in times to diagnosis 
and/or treatment (eg, regional differences; disease 
severity). These data will help us to understand 
where improvements are still needed to decrease the 
time to diagnosis and treatment in order to ensure 
that individuals with MPS I receive the appropriate 
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2003–2009 or before After 2009
  456 284
Europe, n (%) 339 (45.8) 234 (51.3) 105 (37.0)
North America, n (%) 329 (44.5) 187 (41.0) 142 (50.0)
Latin America, n (%) 52 (7.0) 32 (7.0) 20 (7.0)
Asia Pacific, n (%) 20 (2.7) 3 (0.7) 17 (6.0)
Table 2 Demographic and clinical characteristics
Individuals with treatment history
n=740
Gender n (%)
  Female 362 (48.9)
  Male 378 (51.1)
MPS I phenotype n (%)
  Severe 424 (57.3)
  Attenuated 291 (39.3)






Age at diagnosis, year median (IQR) 3.4 (1.2, 6 .6) 0.9 (0.6 to 1.2)
Age distribution, year n (%)
<5 310 (65.8) <1 124 (46.1)
5–<10 93 (19.7) 1–<2 126 (46.8)
≥10 68 (14.4) ≥2 19 (7.1)
Age at start of treatment, year median 
(IQR)
6.1 (2.8 to 12.8) 1.1 (0.7 to 1.4)
Age distribution, year n (%)
<5 203 (43.1) <1 24 (46.1)
5–<10 113 (24.0) 1–<2 126 (46.8)
≥10 155 (32.9) ≥2 19 (7.1)
HSCT treatment history
# HSCT 305
ERT, enzyme replacement therapy; HSCT, haematopoietic stem cell transplant.
METHOdS
Registry
The MPS I Registry (NCT00144794) is a voluntary, observa-
tional global longitudinal database established to capture long- 
term data to help understand the natural history, standards of care 
and treatment outcomes of individuals with MPS I.24 Individuals 
are enrolled in the MPS I Registry by their clinician and data are 
collected both retrospectively and prospectively as previously 
described.24 The Registry is overseen and directed by an indepen-
dent Board of Advisors comprised of physicians who are experts 
in the care of MPS disorders and is sponsored by Sanofi Genzyme 
(Cambridge, MA). All participants (patients or caregivers) provide 
written informed consent for use of anonymised data.
Participants
Observations for individuals in the Registry with either severe or 
attenuated MPS I were included if MPS I treatment was received 
between 1 January 2003 and 31 December 2017. For an obser-
vation to be included, valid dates for diagnosis and start of treat-
ment were required.
data management and analysis
Current, primary treatments for analysis included HSCT or 
ERT (not including peritransplant ERT). For patients with more 
than one HSCT, first HSCT date was used as start of primary 
treatment date. Patients with ERT as primary treatment did not 
receive HSCT. Those for whom HSCT was primary treatment 
and peritransplant ERT was received, ERT was not counted as 
primary treatment.
ERT with laronidase became available in 2003, and the MPS 
I Registry also began enrolling participants in 2003. Data were 
stratified by MPS I phenotype into year intervals at first primary 
MPS I therapy. Four intervals were selected for data analysis: 
in/before 2004 to coincide with initiation of the Registry and 
laronidase ERT and groupings of 2005–2008, 2009–2013 and 
after 2013–2017 to have similar time periods covered by each 
group. Data were also stratified by region where laronidase is 
approved for commercial use, and presented when sufficient 
patient numbers for comparisons were available.
All data were analysed as entered by the clinical site. Descriptive 
statistics include number, percentage, mean, median, SD and IQRs.
RESulTS
Among all participants in the MPS I Registry from January 2003 
to December 2017, 740 had data for age at diagnosis and age at 
treatment. The distribution by region and timing of enrolment 
for individuals with treatment for MPS I are shown in table 1, 
with most participants enrolled before 2009. Distribution of 
participants was evenly divided between Europe (45.8%) and 
North America (44.5%) with a small percentage of individuals 
from Latin America (7%) or Asia Pacific (2.7%).
Table 2 shows the demographic and clinical characteristics 
overall and stratified by first primary treatment (ERT or HSCT). 
Males and females were equally represented. In the entire 
cohort, 424/740 (57.3%) were categorised with severe disease 
and 291/740 (39.3%) with attenuated disease, whereas 25/740 
(3.4%) did not have a phenotype assigned.
HSCT treatment trends over time for pretreatment regimens 
and transplant type and peritransplant ERT are shown in figure 1. 
The trends generally follow the changes in HSCT recommenda-
tions and guidelines that evolved with time and experience. For 
the most recent time interval, cord blood was the most common 
source of stem cells (figure 1A) reported in the Registry, and 
pretransplant conditioning with fludarabine, busulfan and/or 
antithymocyte globulin/serum or antilymphocyte globulin/serum 
were the most common regimens. Peritransplant ERT was used 
pretransplant and/or post- transplant in increasing numbers of 
patients over time (figure 1B).
Age at MPS I diagnosis
Ages at diagnosis stratified by year interval of first primary 
therapy and region are shown for individuals with severe or 
attenuated MPS I for whom ERT was first primary therapy in 
figure 2 and for HSCT as first primary therapy for individuals 
with severe MPS I in figure 3.
Median ages at diagnosis for individuals with attenuated 
disease did not change appreciably over time since introduction 
of ERT and varied between 4.5 and 6 years of age (figure 2A). 
Among all individuals with severe disease receiving ERT as first 
primary therapy (these individuals did also not receive HSCT), 
ages at diagnosis remained fairly stable and varied between 1 
and 2 years of age (figure 2A). Medians (IQR) for the intervals 
before/during 2004, 2005–2008, 2009–2013 and after 2013 to 
2017 were 5.3 (3.4, 9.4), 5.0 (3.0, 10.2), 4.5 (3.3, 8.0) and 6.0 
(4.2, 21.8) years, respectively, for the attenuated group and 1.2 
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Figure 1 Characteristics of HSCT over time for individuals enrolled in 
the MPS I Registry. The type of transplant performed showing the source 
of stem cells is shown in (A). Use of ERT either before or immediately 
after transplant is shown in (B). ERT, enzyme replacement therapy; HSCT, 
haematopoietic stem cell transplants; MPS I, mucopolysaccharidosis 
type I.
Figure 2 Median age in years at MPS I diagnosis by year interval 
for individuals with severe (blue) or attenuated (red) MPS I receiving 
ERT as primary therapy. Global distribution is shown in panel (A). 
Regional distributions are shown for North America (B) and Europe (C). 
Individual medians are shown at the base of each bar and individual 
n’s are shown above the bars. ERT, enzyme replacement therapy; MPS I, 
mucopolysaccharidosis type I.
respectively, for the severe group. Results were similar for indi-
viduals from North America (figure 2B) or Europe (figure 2C).
Median ages at diagnosis for individuals with severe disease 
receiving HSCT as first primary therapy were 0.8 or 0.9 years 
for the four time intervals (figure 3A). Median (IQR) for the 
intervals before/during 2004, 2005–2008, 2009–2013 and after 
2013 to 2017 were 0.8 (0.6, 1.1), 0.9 (0.7, 1.2), 0.8 (0.5, 1.1) 
and 0.9 (0.6, 1.2) years, respectively, and in general, were lower 
than those for individuals with severe disease receiving ERT as 
first therapy. Similar results were noted regionally for individuals 
with severe disease (figure 3B,C).
Time to first primary treatment
Times from diagnosis to first primary treatment stratified by 
phenotype, year interval of first primary therapy and region are 
shown for ERT as first primary therapy in figure 4 and for HSCT 
as first primary therapy in figure 5.
The median durations from diagnosis to first ERT for all indi-
viduals with attenuated or severe MPS I decreased over time 
since introduction of ERT (figure 4A). Medians varied from 5.6 
years for individuals with attenuated disease before or during 
2004 to 2.4 months in the most recent time interval for both 
severe and attenuated disease. Medians (IQR) for the intervals 
before/during 2004, 2005–2008, 2009–2013 and after 2013 to 
2017 were 5.6 (1.9, 11.9), 1.9 (0.4, 5.2), 0.2 (0.1, 0.8) and 0.2 
(0.1, 0.9) years, respectively, for the attenuated group and 2.0 
(0.6, 4.8), 0.8 (0.1, 2.0), 0.2 (0.1, 0.4) and 0.2 (0.1, 0.5) years, 
respectively, for the severe group. When the data were strati-
fied by region, there was a greater duration from diagnosis to 
treatment at the earlier time intervals for individuals in Europe 
(figure 4C) compared with North America (figure 4B). Dura-
tions were similar by region in the more recent time intervals.
The median durations from diagnosis to first HSCT for all 
individuals with severe MPS I were very short for all time inter-
vals (figure 5). Medians (IQR) were 0.2 (0.1, 0.3), 0.1 (0.1, 0.3), 
0.1 (0, 0.2) and 0.1 (0, 0.1) years for intervals before/during 
2004, 2005–2008, 2009–2013 and after 2013 to 2017, respec-
tively. When stratified by North American and European regions 
(not shown), results were similar to the global data.
dISCuSSIOn
First signs and symptoms in individuals with MPS I vary in type, 
severity and age of onset,18 24 25 which can lead to significant diag-
nostic delays due to the non- specific nature of symptoms that are 
suggestive of other diseases. This is particularly true for individuals 
with attenuated MPS I.17–19 24 In a study of the diagnostic history 
of 60 individuals with attenuated MPS I from the USA, Europe and 
Latin America, participants reported that, on average, there was a 
3- year delay between first physician visit and diagnosis for attenu-
ated MPS I, and 20% had delays of 5 years or longer.20 These are 
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Figure 3 Median age in years at MPS I diagnosis by year interval 
for individuals with severe MPS I receiving HSCT as primary therapy. 
Global distribution is shown in panel (A). Regional distributions are 
shown for North America (B) and Europe (C). Individual medians are 
shown at the base of each bar and individual n’s are shown above the 
bars. ERT, enzyme replacement therapy; HSCT, haematopoietic stem cell 
transplants; MPS I, mucopolysaccharidosis type I.
Figure 4 Median duration from diagnosis to first ERT treatment by 
year interval for individuals with severe (blue) or attenuated (red) MPS I 
receiving ERT as primary therapy. Global distribution is shown in panel 
(A). Regional distributions are shown for North America (B) and Europe 
(C). Individual medians are shown at the base of each bar and individual 
n’s are shown at top of bars. ERT, enzyme replacement therapy; MPS I, 
mucopolysaccharidosis type I.
in the USA, Latin America and the Netherlands.21–23 Referrals to 
rheumatologists, orthopaedists, pulmonologists and gastroenterol-
ogists are common once children with MPS I present to paediatri-
cians.26 Regardless of disease severity or initial symptoms, a mean 
of five specialists were consulted before receiving a correct diag-
nosis, highlighting the continued need for awareness education 
within the medical community.20
Our analyses involve a large dataset of diagnosis and treat-
ment trends over time for individuals with MPS I. Time intervals 
for analysis began with approval of laronidase ERT by the FDA 
and EMA in 2003. We found that delays in diagnosis for indi-
viduals with attenuated MPS I have not improved over time. For 
patients not identified by newborn screening (NBS), algorithms 
to raise early clinical suspicion of MPS I based on the range of 
key signs and symptoms,26–29 are available for clinicians so that 
full diagnostic assessment30 of enzyme activity, substrate levels 
(ie, GAGs) and molecular analyses is conducted for appropriate 
patients.30 It is worth noting that despite being a simple test, 
measurement of urinary GAGs is not available in all regions, 
and shipment of urine samples to reference laboratories may be 
difficult to arrange. In addition, urinary GAG levels may not be 
informative in young infants due to lack of standardisation of 
age- related reference ranges,31 The use of dried blood (DBS) for 
measurement of GAGs may provide useful information before 
another sample is requested.32
It is hoped that educational initiatives in combination with 
evolving NBS programmes worldwide,30 31 33–36 will decrease 
time to MPS I diagnosis and treatment. NBS for MPS I have 
used either tandem mass spectrometry or digital microfluidic to 
measure IDUA enzyme activity in DBS.34 36 Follow- up of a posi-
tive NBS result (deficient IDUA activity) should include confir-
matory IDUA enzyme activity in leucocytes, serum or plasma, 
urine GAG analysis and molecular analysis.31 The presence of 
IDUA pseudodeficiency alleles (benign variants) complicates 
NBS for MPS I since the pseudodeficiency alleles are more 
common than pathogenic IDUA variants.37 Pseudodeficiency 
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Figure 5 Median duration from diagnosis to first HSCT treatment by 
year interval for individuals with severe MPS I receiving HSCT as primary 
therapy. Global distribution is shown. HSCT, haematopoietic stem cell 
transplants; MPS I, mucopolysaccharidosis type I.
Second- tier testing measuring either GAG levels or sequencing 
of the IDUA gene using the original DBS has been used to reduce 
the NBS false- positive rate and the follow- up burden.32 36–38 
The MPS I phenotype can be predicted based on genotyping in 
the majority of cases,39 and early treatment initiated based on 
predicted phenotype for severe MPS I (HSCT with or without 
peritransplant ERT) or intravenous ERT for attenuated pheno-
types.31 However, infants with abnormal NBS whose phenotypes 
cannot be positively predicted (ie, IDUA variants of unknown 
significance) require careful clinical and biochemical monitoring 
in order to identify appropriate treatment.31 35 36
In general, individuals with severe MPS I are diagnosed at a 
younger age than those with attenuated disease, in part due to 
the more pronounced somatic symptoms. Our results mirror 
previous reports of MPS I Registry data,17 showing that this 
trend has not changed with time. Early diagnosis of severe MPS 
I is important since HSCT is indicated before 2 years of age, 
and early treatment is associated with better outcomes.14 16 40 
MPS I management decisions following positive NBS depend 
on the integration of biochemical, molecular and clinical assess-
ments.30 31 In the case of a patient identified with severe MPS 
I based on the presence of two pathogenic IDUA variants that 
predict this phenotype, the patient is referred for HSCT and 
potentially early peri- HSCT ERT.31 In accordance with current 
guidelines, HSCT should be ideally performed before 1 year of 
age, and typically not after 2.5 years, although the upper age 
limits vary by geographical region.40 41 A 10 year follow- up 
study showed that peritransplant ERT is associated with good 
outcomes in patients with severe MPS I.10
Interestingly, for individuals in the MPS I Registry with severe 
MPS I for whom ERT was the primary therapy, age at diag-
nosis was older than those with severe MPS I receiving HSCT 
as primary therapy by up to 1.1 years depending on treatment 
interval. This may reflect differences in onset of key somatic 
symptoms in some patients that are hallmarks of severe MPS I 
and drive diagnosis or differences in regional access to health-
care. We should also consider that patients diagnosed after the 
age of 2.0 years may not have been eligible for HSCT according 
to treatment guidelines, driving the patients to ERT mono-
therapy.42 HSCT is not always the primary treatment option for 
patients with severe MPS I. In some countries, the logistical and 
clinical challenges associated with HSCT remain high and fami-
lies may decide not to take the risk. In addition to age restric-
tions, there are individuals with severe MPS I for whom HSCT is 
not a treatment option due to compromised physical state or lack 
of a suitable donor. Thus, patients with severe MPS I may still 
receive only ERT, although outcomes with ERT monotherapy in 
patients with severe MPS I are inferior to those obtained with 
early HSCT.42
While multiple studies have investigated delays between 
symptom onset and MPS I diagnosis, there is much less known 
regarding time between diagnosis and treatment onset. The dura-
tion from diagnosis to first treatment with ERT has improved 
substantially over time since introduction of laronidase ERT in 
2003, from a median of over 5 years to less than 2 months. Early 
treatment with ERT has been shown to considerably improve 
patient outcomes during long- term therapy.12 13 15 We anticipate 
that NBS programmes will result in decreased times to diag-
nosis and treatment with implementation and evolution of best 
management practices.31 35 42
Strengths and weaknesses of study
As with all observational studies, there exists the potential for 
ascertainment and reporting biases due in part to the volun-
tary and observational nature of the MPS I Registry, which may 
impact the generalisability of the findings. The analyses included 
registry participants that subsequently died after data were 
captured on age at diagnosis and time to primary treatment. 
While a potential for bias is introduced by including patients 
that died who ultimately may have had severe disease, the bias 
would likely result in shorter times to diagnosis. The limitations 
of this analysis include the small numbers of individuals due 
to the nature of rare diseases, as well as limited data available 
in some regions. In particular, the smaller number of individ-
uals from Latin America and Asia limit the comparison of these 
regions’ trends with those for North America and Europe and 
make it difficult to compare factors such as healthcare system 
practices that may affect age at diagnosis and time to treatment. 
Specifically, there are significant differences in the healthcare 
practices of individual countries with respect to reimbursement 
of ERT and HSCT that may impact time to treatment, as well 
as challenges that patients and their families face in travelling to 
specialty centres for ERT infusions and/or transplants.
COnCluSIOn
Early diagnosis is crucial for the best therapeutic outcomes 
with both ERT and HSCT to reduce disease progression before 
irreversible organ and tissue damage occur. The present study 
demonstrates that diagnosis of MPS I is delayed. However, time 
to treatment initiation, once individuals have been diagnosed, 
has improved substantially in the last 15 years for patients with 
either severe or attenuated MPS I. Efforts to improve early 
diagnosis are needed to ensure that patients receive appropriate 
treatment at the optimal time. These data illustrate that across 
regions, improvement in MPS I awareness is still needed.
Contributors RG contributed to the conception and design of the manuscript, 
analysis and interpretation of the data, drafted and revised the manuscript, approved 
the final version and is accountable for all aspects of the manuscript. NM contributed 
to interpretation of the data, revised the manuscript, approved the final version and 
is accountable for all aspects of the manuscript. MD contributed to interpretation 
of the data and revision of the manuscript, approved the final version and is 
accountable for all aspects of the manuscript. HK contributed to the conception and 
design of the manuscript, analysis and interpretation of the data, drafted and revised 
the manuscript, approved the final version and is accountable for all aspects of the 


























679Giugliani R, et al. Arch Dis Child 2021;106:674–679. doi:10.1136/archdischild-2020-319040
Original research
and interpretation of the data, drafted and revised the manuscript, approved the 
final version and is accountable for all aspects of the manuscript.
Funding The study was funded by Sanofi Genzyme, Cambridge, Massachusetts, 
USA. Patrice C Ferriola, PhD, provided medical writing and editing assistance and 
was funded by Sanofi Genzyme.
Competing interests RG has received consultant/speaker honoraria/fees and/
or served on advisory boards for Actelion, Amicus, Biomarin, Inventiva, RegenxBio, 
Sanofi Genzyme, Sobi, Takeda and Ultragenyx, conducts contracted research for 
BioMarin, JCR, Lysogene, RegenxBio, Sanofi Genzyme, Takeda, and Ultragenyx and 
is a member of the International Board of Advisors of the MPS I Registry. NM is a 
consultant for Biomarin, Sanofi Genzyme, Lysogene, Shire and Sobi, has received 
grants/research support from Amicus, Biomarin, Sanofi Genzyme and Shire and has 
received honoraria and/or travel grants from Actelion, Amicus, BioMarin, Chiesi 
Farmaceutici S.p.A., Sanofi Genzyme and Shire. HK was an employee of Sanofi 
Genzyme at the time of the study.MD has received consultant/speaker honoraria 
and/or travel grants from Biomarin, Sanofi Genzyme, Regenxbio, Bluebird Bio, 
Ultragenyx. JM received consultant/speaker honoraria/fees and served on advisory 
boards for BioMarin, Denali, Eloxx, RegenxBio, Sangamo, Sanofi Genzyme and Shire, 
is a PI for a Phase I/II and Phase II/III intrathecal enzyme replacement clinical trials 
for MPS II and a Phase I/II gene editing clinical trial for MPS II and is a member of 
the International Board of Advisors of the MPS I Registry.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data may be obtained from a third party and 
are not publicly available. The data that support the findings of this study can be 
requested by MPS I Registry participants through a MPS I Registry Data Analyses 
Request form. The data are not publicly available due to privacy or ethical 
restrictions. For additional information, please contact  rare dise aser egis tries@ sanofi. 
com.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId id
Roberto Giugliani http:// orcid. org/ 0000- 0001- 9655- 3686
RefeRences
 1 Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology 2011;50 Suppl 
5:v4–12.
 2 Moore D, Connock MJ, Wraith E, et al. The prevalence of and survival in 
mucopolysaccharidosis I: Hurler, Hurler- Scheie and Scheie syndromes in the UK. 
Orphanet J Rare Dis 2008;3:24–30.
 3 Federhen A, Pasqualim G, de Freitas TF, et al. Estimated birth prevalence of 
mucopolysaccharidoses in Brazil. Am J Med Genet A 2020;182:469–83.
 4 Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Schriver C, Beaudet A, Sly W, 
et al, eds. The metabolic and molecular basis of inherited disease. New York: McGraw 
Hill, 2001: p. 3421–52.
 5 Thomas JA, Beck M, Clarke JTR, et al. Childhood onset of Scheie syndrome, the 
attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 2010;33:421–7.
 6 Tolar J, Orchard PJ. Alpha- L- Iduronidase therapy for mucopolysaccharidosis type I. 
Biologics 2008;2:743–51.
 7 Muenzer J, Wraith JE, Clarke LA, et al. Mucopolysaccharidosis I: management and 
treatment guidelines. Pediatrics 2009;123:19–29.
 8 de Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/
or hematopoietic stem cell transplantation at diagnosis in patients with 
mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J 
Rare Dis 2011;6:55–62.
 9 Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement 
therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005;6:489–506.
 10 Ghosh A, Miller W, Orchard PJ, et al. Enzyme replacement therapy prior to 
haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year 
combined experience of 2 centres. Mol Genet Metab 2016;117:373–7.
 11 Giugliani R. Mucopolysacccharidoses: from understanding to treatment, a century of 
discoveries. Genet Mol Biol 2012;35:924–31.
 12 Laraway S, Breen C, Mercer J, et al. Does early use of enzyme replacement therapy 
alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol 
Genet Metab 2013;109:315–6.
 13 Muenzer J. Early initiation of enzyme replacement therapy for the 
mucopolysaccharidoses. Mol Genet Metab 2014;111:63–72.
 14 Poe MD, Chagnon SL, Escolar ML. Early treatment is associated with improved 
cognition in Hurler syndrome. Ann Neurol 2014;76:747–53.
 15 Gabrielli O, Clarke LA, Bruni S, et al. Enzyme- Replacement therapy in a 5- month- 
old boy with attenuated presymptomatic MPS I: 5- year follow- up. Pediatrics 
2010;125:e183–7.
 16 Aldenhoven M, Wynn RF, Orchard PJ, et al. Long- Term outcome of Hurler syndrome 
patients after hematopoietic cell transplantation: an international multicenter study. 
Blood 2015;125:2164–72.
 17 D’Aco K, Underhill L, Rangachari L, et al. Diagnosis and treatment trends 
in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr 
2012;171:911–9.
 18 Vijay S, Wraith JE. Clinical presentation and follow- up of patients with the attenuated 
phenotype of mucopolysaccharidosis type I. Acta Paediatr 2005;94:872–7.
 19 Beck M, Arn P, Giugliani R, et al. The natural history of MPS I: global perspectives from 
the MPS I Registry. Genet Med 2014;16:759–65.
 20 Bruni S, Lavery C, Broomfield A. The diagnostic journey of patients with 
mucopolysaccharidosis I: a real- world survey of patient and physician experiences. 
Mol Genet Metab Rep 2016;8:67–73.
 21 de Ru MH, Bouwman MG, Wijburg FA, et al. Experiences of parents and patients with 
the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the 
ethical debate on newborn screening. Mol Genet Metab 2012;107:501–7.
 22 Kuiper G- A, Meijer OLM, Langereis EJ, et al. Failure to shorten the diagnostic delay in 
two ultra- orphan diseases (mucopolysaccharidosis types I and III): potential causes 
and implications. Orphanet J Rare Dis 2018;13:2.
 23 Vieira T, Schwartz I, Muñoz V, et al. Mucopolysaccharidoses in Brazil: what happens 
from birth to biochemical diagnosis? Am J Med Genet A 2008;146A:1741–7.
 24 Pastores GM, Arn P, Beck M, et al. The MPS I registry: design, methodology, 
and early findings of a global disease Registry for monitoring patients with 
Mucopolysaccharidosis Type I. Mol Genet Metab 2007;91:37–47.
 25 Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH 
(Hurler syndrome). Acta Paediatr 1995;84:337–9.
 26 Cimaz R, Coppa GV, Koné-Paut I, et al. Joint contractures in the absence of 
inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J 
2009;7:18–25.
 27 Tylki- Szymańska A, De Meirleir L, Di Rocco M, et al. Easy- To- Use algorithm would 
provide faster diagnoses for mucopolysaccharidosis type I and enable patients to 
receive earlier treatment. Acta Paediatr 2018;107:1402–8.
 28 Guffon N, Journeau P, Brassier A, et al. Growth impairment and limited range 
of joint motion in children should raise suspicion of an attenuated form of 
mucopolysaccharidosis: expert opinion. Eur J Pediatr 2019;178:593–603.
 29 Martins AM, Lindstrom K, Kyosen SO, et al. Short stature as a presenting symptom 
of attenuated Mucopolysaccharidosis type I: case report and clinical insights. BMC 
Endocr Disord 2018;18:83.
 30 Kubaski F, de Oliveira Poswar F, Michelin- Tirelli K, et al. Diagnosis of 
Mucopolysaccharidoses. Diagnostics 2020;10:172.
 31 Clarke LA, Atherton AM, Burton BK, et al. Mucopolysaccharidosis Type I newborn 
screening: best practices for diagnosis and management. J Pediatr 2017;182:363–70.
 32 Kubaski F, Suzuki Y, Orii K, et al. Glycosaminoglycan levels in dried blood spots 
of patients with mucopolysaccharidoses and mucolipidoses. Mol Genet Metab 
2017;120:247–54.
 33 Lin S- P, Lin H- Y, Wang T- J, et al. A pilot newborn screening program for 
Mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 2013;8:147.
 34 Hopkins PV, Campbell C, Klug T, et al. Lysosomal storage disorder screening 
implementation: findings from the first six months of full population pilot testing in 
Missouri. J Pediatr 2015;166:172–7.
 35 Parini R, Broomfield A, Cleary MA, et al. International working group identifies need 
for newborn screening for mucopolysaccharidosis type I but states that existing 
hurdles must be overcome. Acta Paediatr 2018;107:2059–65.
 36 Donati MA, Pasquini E, Spada M, et al. Newborn screening in mucopolysaccharidoses. 
Ital J Pediatr 2018;44:126.
 37 Taylor JL, Clinard K, Powell CM, et al. The North Carolina experience with 
Mucopolysaccharidosis Type I newborn screening. J Pediatr 2019;211:193–200.
 38 Polo G, Gueraldi D, Giuliani A, et al. The combined use of enzyme activity and 
metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type 
I. Clin Chem Lab Med 2020. doi:10.1515/cclm-2020-0064. [Epub ahead of print: 20 
May 2020].
 39 Clarke LA, Giugliani R, Guffon N, et al. Genotype- Phenotype relationships in 
mucopolysaccharidosis type I (MPS I): insights from the International MPS I registry. 
Clin Genet 2019;96:281–9.
 40 Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for 
mucopolysaccharidosis patients is safe and effective: results after implementation of 
international guidelines. Biol Blood Marrow Transplant 2015;21:1106–9.
 41 Parini R, Deodato F, Di Rocco M, et al. Open issues in Mucopolysaccharidosis type 
I- Hurler. Orphanet J Rare Dis 2017;12:112.
 42 Eisengart JB, Rudser KD, Xue Y, et al. Long- Term outcomes of systemic therapies 





















hild: first published as 10.1136/archdischild-2020-319040 on 2 N
ovem
ber 2020. D
ow
nloaded from
 
